Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors.
作者信息
Chong Pei Pei, Rubin Joshua B, Abdullah Maha, Conforti Fabio, Klein Sabra L, Liu Wanli
机构信息
School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Malaysia.
School of Medicine, Washington University at St. Louis, St. Louis, MO, United States.
出版信息
Front Immunol. 2022 Jun 16;13:941254. doi: 10.3389/fimmu.2022.941254. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors.社论：免疫检查点抑制剂因年龄和性别因素产生的差异疗效
Front Immunol. 2022 Jun 16;13:941254. doi: 10.3389/fimmu.2022.941254. eCollection 2022.
2
Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy.免疫检查点抑制剂和细胞治疗在淋巴瘤免疫治疗中的应用。
Clin Exp Immunol. 2021 Jul;205(1):1-11. doi: 10.1111/cei.13592. Epub 2021 Mar 28.
3
Immune checkpoints and cancer development: Therapeutic implications and future directions.免疫检查点与癌症发生：治疗意义与未来方向
Pathol Res Pract. 2021 Jul;223:153485. doi: 10.1016/j.prp.2021.153485. Epub 2021 May 15.
4
Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?免疫检查点抑制剂：转移性去势抵抗性前列腺癌的有前途的治疗选择？
Int J Mol Sci. 2021 Apr 29;22(9):4712. doi: 10.3390/ijms22094712.
5
Immunotherapy and predictive immunologic profile: the tip of the iceberg.免疫治疗和预测性免疫特征：冰山一角。
Med Oncol. 2021 Mar 31;38(5):51. doi: 10.1007/s12032-021-01497-8.
6
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.免疫检查点抑制剂（程序性细胞死亡蛋白 1 与程序性细胞死亡配体 1）在癌症患者中的应用：系统评价和荟萃分析。
JAMA Oncol. 2020 Mar 1;6(3):375-384. doi: 10.1001/jamaoncol.2019.5367.
7
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.与免疫检查点抑制剂相关的极重度免疫相关不良事件的决定因素：法国 REISAMIC 注册前瞻性研究。
Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7.
8
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.YM101：一种同时靶向 TGF-β和 PD-L1 的双特异性抗体的构建、表达及增强的抗肿瘤活性。
J Hematol Oncol. 2021 Feb 16;14(1):27. doi: 10.1186/s13045-021-01045-x.
9
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.免疫检查点抑制剂联合治疗肝细胞癌的挑战。
J Hepatol. 2020 Feb;72(2):307-319. doi: 10.1016/j.jhep.2019.09.025.
10
Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer.性别对晚期非小细胞肺癌接受免疫检查点抑制剂治疗的患者疗效的影响。
Cancer Med. 2019 Jul;8(8):4023-4031. doi: 10.1002/cam4.2280. Epub 2019 Jun 4.
引用本文的文献
1
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study.免疫治疗的 sided effect 中的性别差异：优化癌症治疗的可能线索 (G-DEFINER)：一项观察性前瞻性多中心研究的研究方案。
Acta Oncol. 2024 Apr 21;63:213-219. doi: 10.2340/1651-226X.2024.24179.
2
Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series.替雷利珠单抗联合吉西他滨和顺铂作为肌层浸润性膀胱癌的新辅助治疗方案：病例系列
Ann Med Surg (Lond). 2023 Nov 20;86(1):245-251. doi: 10.1097/MS9.0000000000001533. eCollection 2024 Jan.
本文引用的文献
1
Sexual Dimorphic Responses in Lymphocytes of Healthy Individuals after Consumption.健康个体摄入后淋巴细胞中的性二态性反应。
Front Immunol. 2017 Jun 9;8:680. doi: 10.3389/fimmu.2017.00680. eCollection 2017.
2
Gender effect on in vitro lymphocyte subset levels of healthy individuals.健康个体体外淋巴细胞亚群水平的性别效应。
Cell Immunol. 2012;272(2):214-9. doi: 10.1016/j.cellimm.2011.10.009. Epub 2011 Oct 25.
Zotero 插件